STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway

References

• Zhu Q, Zhang X, Zai H-Y, et al. circSLC8A1 sponges miR-671 to regulate breast cancer tumorigenesis via PTEN/PI3k/Akt pathway. Genomics. 2021;113(1):398–410.
   PubMed Web of Science ®Google Scholar
• Wm Nor W, Chung I, Said N. MicroRNA-548m Suppresses Cell Migration and Invasion by Targeting Aryl Hydrocarbon Receptor in Breast Cancer Cells. Oncol Res. 2021;28(6):615–629.
   PubMed Web of Science ®Google Scholar
• Yuan X, Qian N, Ling S, et al. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells. Theranostics. 2021;11(3):1429–1445.
   PubMed Web of Science ®Google Scholar
• Emens LA. Breast Cancer Immunotherapy: facts and Hopes. Clin Cancer Res. 2018;24(3):511–520.
   PubMed Web of Science ®Google Scholar
• Tsoukalas N, Kiakou M, Tsapakidis K, et al. PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer. J Buon. 2019;24(3):883–888.
   PubMed Web of Science ®Google Scholar
• Dermani FK, Samadi P, Rahmani G, et al. PD-1/PD-L1 immune checkpoint: potential target for cancer therapy. Journal of Cellular Physiology. 2019;234(2):1313–1325.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen M, Nie H, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Human Vaccines & Immunotherapeutics. 2019;15(5):1111–1122.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang N, Zhou J, et al. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunol Res. 2018;6(2):178–188.
   PubMed Web of Science ®Google Scholar
• Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. 2018;24(1):47–53.
   PubMed Web of Science ®Google Scholar
• Reddy SM, Carroll E, Nanda R. Atezolizumab for the treatment of breast cancer. Expert rev anticancer ther. 2020;20(3):151–158.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020;383(14):1328–1339.
   PubMed Web of Science ®Google Scholar
• Noguchi E, Shien T, Iwata H. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. Jpn J Clin Oncol. 2021;51(3):321–332.
   PubMed Web of Science ®Google Scholar
• Heimes AS, Schmidt M. Atezolizumab for the treatment of triple-negative breast cancer. Expert Opin Investig Drugs. 2019;28(1):1–5.
   PubMed Web of Science ®Google Scholar
• Shae D, Becker KW, Christov P. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nature Nanotechnology. 2019;14(3):269–278.
   PubMed Web of Science ®Google Scholar
• Corrales L, McWhirter SM, Dubensky TW, et al. The host STING pathway at the interface of cancer and immunity. J Clin Investig. 2016;126(7):2404.
   PubMed Web of Science ®Google Scholar
• Chen YP, Xu L, Tang TW, et al. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer. ACS Appl Mater Interfaces. 2020;12(51):56741–56752.
   PubMed Web of Science ®Google Scholar
• Yang H, Lee WS, Kong SJ, et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest. 2019;129(10):4350–4364.
   PubMed Web of Science ®Google Scholar
• Abd Razak N, Yeap SK, Alitheen NB. Eupatorin Suppressed Tumor Progression and Enhanced Immunity in a 4T1 Murine Breast Cancer Model. Integrative Cancer Therapies. 2020;19:1534735420935625.
   Web of Science ®Google Scholar
• Roda E, De Luca F, Di Iorio C, et al. Novel Medicinal Mushroom Blend as a Promising Supplement in Integrative Oncology: a Multi-Tiered Study using 4T1 Triple-Negative Mouse Breast Cancer Model. Int J Mol Sci. 2020;21(10):3479.
   Web of Science ®Google Scholar
• Motedayen Aval L, Pease JE, Sharma R, et al. Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020;9(10):3323.
   PubMed Web of Science ®Google Scholar
• Go EJ, Yang H, Chon HJ, et al. Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy. Cancer. 2020;12(11):3123.
   Google Scholar
• Cruceriu D, Baldasici O, Balacescu O. The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches. Cell oncol (Dordrecht). 2020;43(1):1–18
   PubMed Web of Science ®Google Scholar
• Ma Y, Ren Y, Dai Z-J, et al. IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients. Adv Clin Exp Med. 2017;26(3):421–426.
   PubMed Web of Science ®Google Scholar
• Wang K, Ren Y, Liu Y, et al. Tumor Necrosis Factor (TNF)-α-Induced Protein 8-like-2 (TIPE2) Inhibits Proliferation and Tumorigenesis in Breast Cancer Cells. Oncol Res. 2017;25(1):55–63.
   PubMed Web of Science ®Google Scholar
• Fujio K, Yamamoto K, Okamura T. Overview of LAG-3-Expressing, IL-10-Producing Regulatory T Cells. Curr Top Microbiol Immunol. 2017;410:29–45.
   PubMed Web of Science ®Google Scholar
• Johnson BM, Uchimura T, Gallovic MD, et al. STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways. J immunolo (Baltimore, Md.: 1950). 2021;206(9):2015–2028.
   PubMed Web of Science ®Google Scholar
• Liu M, Zhou J, Chen Z, et al. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy. J Pathol. 2017;241(1):10–24.
   PubMed Web of Science ®Google Scholar
• van der Leun AM, Thommen DS. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218–232.
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. Journal of Cellular Physiology. 2019;234(6):8509–8521.
   PubMed Web of Science ®Google Scholar
• Ghaffari A, Peterson N, Khalaj K, et al. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. Br J Cancer. 2018;119(4):440–449.
   PubMed Web of Science ®Google Scholar
• Sivick KE, Desbien AL, Glickman LH, et al. Magnitude of Therapeutic STING Activation Determines CD8(+) T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018;25(11):3074–3085.e5.
   PubMed Web of Science ®Google Scholar
• Guo Y, Xie YQ, Gao M. Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity. Nature Immunology. 2021;22(6):746–756.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–787.
   PubMed Web of Science ®Google Scholar
• Shang B, Liu Y, Jiang S-J, et al. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5(1):15179.
   PubMed Web of Science ®Google Scholar
• Ohkuri T, Ghosh A, Kosaka A, et al. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res. 2014;2(12):1199–1208.
   PubMed Web of Science ®Google Scholar
• Palmer C, Facchini FA, Jones RP, et al. Synthetic glycolipid-based TLR4 antagonists negatively regulate TRIF-dependent TLR4 signalling in human macrophages. Innate immun. 2021;27(3):275–284.
   PubMed Web of Science ®Google Scholar
• Peng GL, Li L, Guo Y-W, et al. CD8(+) cytotoxic and FoxP3(+) regulatory T lymphocytes serve as prognostic factors in breast cancer. Am J Transl Res. 2019;11(8):5039–5053.
   PubMed Web of Science ®Google Scholar
• Carpi A, Nicolini A, Antonelli A, et al. Cytokines in the management of high risk or advanced breast cancer: an update and expectation. Curr Cancer Drug Targets. 2009;9(8):888–903.
   PubMed Web of Science ®Google Scholar
• Doherty MR, Parvani JG, Tamagno I, et al. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer. Breast Cancer Res. 2019;21(1):54.
   PubMedGoogle Scholar
• Yang X, Zhang X, Fu M, et al. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell. 2014;25(1):37–48.
   PubMed Web of Science ®Google Scholar
• Ren D, Qin G, Zhao J, et al. Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer. Am J Cancer Res. 2020;10(9):2851–2864.
   PubMed Web of Science ®Google Scholar
• Jorgovanovic D, Song M, Wang L, et al. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020;8(1):49.
   PubMed Web of Science ®Google Scholar
• Sen T, Rodriguez BL, and Chen L, et al. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. 2019;9(5): 646–661 .
   Google Scholar
• Zemek RM, and De Jong E. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Sci Transl Med. 2019;11(501): eaav7816.
   PubMed Web of Science ®Google Scholar